Bevacizumab + Temozolomide + Temozolomide + Irinotecan + Bevacizumab + Topotecan + Temozolomide + Dinutuximab Beta + Cyclophosphamide
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroblastoma
Conditions
Neuroblastoma
Trial Timeline
Jul 1, 2013 → Feb 1, 2026
NCT ID
NCT02308527About Bevacizumab + Temozolomide + Temozolomide + Irinotecan + Bevacizumab + Topotecan + Temozolomide + Dinutuximab Beta + Cyclophosphamide
Bevacizumab + Temozolomide + Temozolomide + Irinotecan + Bevacizumab + Topotecan + Temozolomide + Dinutuximab Beta + Cyclophosphamide is a phase 2 stage product being developed by Roche for Neuroblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT02308527. Target conditions include Neuroblastoma.
What happened to similar drugs?
0 of 1 similar drugs in Neuroblastoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02308527 | Phase 2 | Active |
Competing Products
20 competing products in Neuroblastoma